Brief: Alterity Therapeutics Says Regulatory Approval To Proceed With Phase 2 Trial In Italy
23/06/2022 02:22
June 23 (Reuters) - Alterity Therapeutics ATH.AX :
* REGULATORY APPROVAL TO PROCEED WITH PHASE 2 TRIAL IN
ITALY-ATH.AX
Source text for Eikon: ID:nASX8D3q0
Further company coverage: ATH.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital